Exchange: NYSEMkt·Updated 04:18 AM EST
PLX logo

PLX Protalix BioTherapeutics Inc.

$3.05
$0.02
(0.66%)
Pre-Market
Prev Close $3.03
Reported EarningsNov 10
Mkt Cap$257.17M
Vol149.00

About PLX

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
71

Bullish Sentiment

How do you feel about PLX?

BambooPanda
$PLX Bit late, been busy. My take on Q3 earnings: - As expected on Q2 highest finished goods Q3 revenues were higher than Q2. - Q3 finished goods at a new record high of 20.8M, 16% higher than Q2's 17.9M which was itself 17% higher than Q1's 15.4M, which as 48% higher than the 10.4M from Q4 2025. Logic would submit Zack's Q4 earnings are wrong and we should see Q4 revenues higher than Q3. - Management said uptake is accelerating in all geographies particularly EU with E4W. - Brazil, high Fabry population, approved both regimens at the same time. - Management increased total Fabry market capture to 25% - mentioned management expects moving to next tier royalty within 6 months, I assume means to 20%. 3.2B*25% market = 800M*20% royalty = 160M to PLX And by 2031 one might expect at least 25% royalty = 200M to PLX With baseline 15x royalty revenue multiple = MC of 2.4B to 3B This does not include potential positive PRX-115 Phase 3/approval by then too. Excellent.
15
charleston_invest
$PLX Besides Dror's usual less than inspiring representation of Protalix, I think we may have learned one thing. It seems there is good reason to assume that this quarter's $0.05 EPS may be close to considering as a baseline which would translate to $0.20 EPS for a year. With a current SP of about $2.5 that translates to only a 12.5 P/E ratio (low). No value at all being given to PRX-115 or any future drugs based on their unique technology. So we have here a small cap Bio with positive EPS while supporting the cost of trials for their next pipeline drug with no debt and about 25% of their value in Cash on hand. I believe we call this a Unicorn. It has been said before, that if Protalix was named something else and only had the Gout drug in trial development, racking up losses quarter after quarter eating through what limited non-growing capital it had left, they probably would be valued at a higher market cap than Protalix. It's crazy to think that, but it is most likely the truth.
17
charleston_invest
$PLX They are spending around $0.40/share on R&D development for their pipeline drugs. At an average P/E of 20 for the markets, this equates to about an $8 SP. If you add $0.20 EPS they have now to this $0.40 in R&D - it totals $0.60 EPS and using a 20 P/E ratio (market avg) you get a stock price of $12. This means that Protalix is putting a lot of value into the pipeline drugs, but the market is not valuing it that way at all. Basically the market is giving no value to the pipeline which is where the huge undervaluation lies - you can debate the magnitude, but not the existence.
11
BambooPanda
$PLX While it's hard to know how the earnings are going to look with lumpiness, there are a few things I find interesting. - One is that the last Q2 earnings Finished Goods inventory reached a record high, which was 17% higher than the Q1 inventory which itself was a record high at 48% higher than Q4 2025. This hopefully would indicate even higher earnings for this Q3 than Q2, as logically why would you invest another 17% more in finished good inventory over the prior quarter if you or Chiesi weren't planning on selling 17% more product. - Another thing is that both the ACR meeting and the Q3 earnings are on the same day, 10th November. Q3 earnings at 8am Eastern time and the ACR presentation at 10:30am Eastern time. It is unnecessary to do them on the same day as last day for publishing earnings is 16th November. So one hopes this means they have something good they want to say publicly which Dror can roll with/show off at the meeting an hour later. Thoughts?
11
PLX_BULLS
$PLX Going with revenues of 23$ million with a confirming timeline of the FDA expansion of 1 dose by Chiesi.
11
charleston_invest
$PLX One would hope the timing of the ER foretells it not to be a bad report. Why would you schedule an ER just before starting an investor conference unless you felt it would shine a positive light. Of course, this would be the thinking of a normal management team - not sure I should expect the same logic from this one.
11
jonnybest
$PLX The chart look good ytd but if you zoom out, the major resistance is around 3.20. Need to break that and close above and rebound on it couple of days to end the curse.
10
Andrea31
$PLX I was busy today, and then, at the end of the day, I suddenly received a gift from plx.
10
WallStpolitician
$PLX What Dror + Gilad Mamlok just said on the call (That Wasn't In The Press Release) 1. Elfabrio — is Q3 a new plateau? (HC Wainwright) asked: Is this a new baseline for Chiesi / Elfabrio revenue, or a one-off? Dror: We do see a very nice year from Chiesi... We expect this increase to continue. We're not going to provide guidance now, but we are going to do the same for 2027 once we publish our annual results…Chiesi has a good team, long-term plan, they execute well etc… Translation to me: Dror is NOT calling Q3 a peak He expects the increase to continue, but he won't give 2027 guidance until the annual results (March) That's exactly his discipline from my conversations guys 😎 "No interim PRs, only communicate at real moments"
10
BambooPanda
$PLX Nobody checking up on our friends at Takeda? They issued earnings for the July - September quarter today. Interestingly they have reorganised their geographic classification. Forever they had EUCAN,ncombining EU+Canada sales, but this dominated by EU sales. Even on population Canada is less that 9% of the population the EMA covers. 2026 this quarter Europe sales reported at 9.6B Yen on AER, which once again is misleading as they should be reporting on CER like everyone else , especially as year/year the Yen has depreciated vs the Euro by about 6%. Thus the 9.6B actually equates to about 9BYen on CER. Which means Replagal Sales have dropped -2.2% vs last year, when subtracting assumed Canada sales beforehand, perhaps Europe drop of -2%, and flat vs last quarter. I might expect Elfabrio & Replagal to be supported by Fabrazyme supply issues, but I expect Replagal to keep trending down over time. Still equal worst Replagal sales since tracking this from 2022.
10
brunoq14
$PLX We got an earnings and revenue beat plus a presentation of data reflecting positively on the market opportunity of 115, as well as Stifel later today. I'll take that.
9
calemay
$PLX Another cup and handle forming…fy27 hoping to hit $5 and graduate from being a penny stock
9
ed29
$PLX $PLX levels I mapped from 10 years of month-end closes: Threes: $3.19 is the big one. Stock hit it in Feb 2026 and was $2.17 by month end March. Same thing in Apr 2025 at ~$3.10, down to $1.55 by May. Two rejections. $3.75 to $3.87 is next (2020 range). Fours: $4.90 is the wall. Month-end closes of exactly $4.90 in Jul 2018, Oct 2018 and Feb 2021, plus five more from $4.69 to $4.86 in 2018 and 2019. Fives: no month-end close above $4.90 since Sep 2018. The last close in the fives was $5.40 in Mar 2018, then it dropped to $4.10. Support: $2.33 to $2.43, then $2.05 to $2.20. Yeah yeah I know many of you have been here for a while and know all this but just posting it to keep it fresh for the knew folks.
8
Llamalamb2921
$PLX They continue to move forward. I think no news is good news. Clearly they keep their cards close to their chest. I think they believe that anything they say can potentially be used against them! They state the facts with very little embellishment. Ultimately all that matters is their endgame which we don’t know yet.
8
brunoq14
$PLX Two things that I'm looking forward to hearing in the earnings presentation are further development of the prospects of four week Elfabrio dosing being expanded to the United States, a theme first broached in the CFO's Morgan Stanley presentation. Also looking forward to hearing that the RELEASE trial is nearly fully enrolled.
8
brunoq14
$PLX Increasing brokerage attention, Morgan Stanley, Stifel. Approaching full enrollment of Phase 2 trial in severe gout.
8
brickwalr
$PLX Partner Chiesi obtained marketing authorization in Brazil from the Agência Nacional de Vigilância Sanitária (ANVISA) on October 5th for both two-week and four-week Elfabrio dosing regimens. I don't remember seeing this anywhere.
7
CliffordCapital
$PLX second highest weekly close since may 2023. Highest previous close was one cent higher at 3.06$ in February 2026. After all this waiting we deserve to see 5$. I want it asap please… market always prices in the future so make it happen MM.
6
jcon777
$PLX Up over 9% with volume over 3M again. It appears some big investors are joining us.
7
Thinkapp
$PLX my first enter was above 7 and a long suffering 6 years waiting and averaging down is finally rewarded. I will hold it tight till at least 10, then 20 if i could. I guess this will be acquired in next couple of years.
7

Advertisement|Remove ads.